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Abstract
Purpose Increased type I interferon is considered relevant to
the pathology of a number of monogenic and complex disor-
ders spanning pediatric rheumatology, neurology, and derma-
tology. However, no test exists in routine clinical practice to
identify enhanced interferon signaling, thus limiting the ability
to diagnose and monitor treatment of these diseases. Here, we
set out to investigate the use of an assay measuring the expres-
sion of a panel of interferon-stimulated genes (ISGs) in chil-
dren affected by a range of inflammatory diseases.
Design, Setting, and Participants A cohort study was con-
ducted between 2011 and 2016 at the University of
Manchester, UK, and the Institut Imagine, Paris, France.
RNA PAXgene blood samples and clinical data were collected
from controls and symptomatic patients with a genetically
confirmed or clinically well-defined inflammatory phenotype.
The expression of six ISGs was measured by quantitative
polymerase chain reaction, and the median fold change was
used to calculate an interferon score (IS) for each subject com-
pared to a previously derived panel of 29 controls (where +2
SD of the control data, an IS of >2.466, is considered as
abnormal). Results were correlated with genetic and clinical
data.
Results Nine hundred ninety-two samples were analyzed
from 630 individuals comprising symptomatic patients across
24 inflammatory genotypes/phenotypes, unaffected heterozy-
gous carriers, and controls. A consistent upregulation of ISG
expression was seen in 13 monogenic conditions (455 sam-
ples, 265 patients; median IS 10.73, interquartile range (IQR)
5.90–18.41), juvenile systemic lupus erythematosus (78 sam-
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ples, 55 patients; median IS 10.60, IQR 3.99–17.27), and ju-
venile dermatomyositis (101 samples, 59 patients; median IS
9.02, IQR 2.51–21.73) compared to controls (78 samples, 65
subjects; median IS 0.688, IQR 0.427–1.196), heterozygous
mutation carriers (89 samples, 76 subjects; median IS 0.862,
IQR 0.493–1.942), and individuals with non-molecularly de-
fined autoinflammation (89 samples, 69 patients; median IS
1.07, IQR 0.491–3.74).
Conclusions and Relevance An assessment of six ISGs can be
used to define a spectrum of inflammatory diseases related to
enhanced type I interferon signaling. If future studies demon-
strate that the IS is a reactive biomarker, this measure may
prove useful both in the diagnosis and the assessment of treat-
ment efficacy.
Keywords Interferon . interferonopathy . autoinflammation .
autoinflammatory disease
Introduction
Given their potent and broad effects, the type I interferons rep-
resent both key molecules in anti-viral defense and potential
mediators of inflammatory disease. As such, the induction,
transmission, and resolution of the interferon response are tight-
ly regulated. Mendelian disorders associated with a persistent
upregulation of type I interferons, the so-called type I
interferonopathies, and related non-monogenic phenotypes,
most particularly systemic lupus erythematosus (SLE) and der-
matomyositis (DM), represent examples of a disturbance of the
homeostatic control of this complex system [1–4]. The recog-
nition of these disorders will become of increasing clinical im-
portance as Banti-interferon^ treatments are developed [5].
Surprisingly, no routine laboratory test exists in current
medical practice for the assessment of type I interferon signal-
ing. Although a cytopathic protection assay, measuring anti-
viral activity in patient material, was central in defining the
first described monogenic type I interferonopathy, Aicardi-
Goutières syndrome (AGS), this assay is neither widely avail-
able nor easily automated [6, 7]. Furthermore, type I interferon
mRNA and protein assays in peripheral blood mononuclear
cells (PBMCs) have proven insensitive as disease biomarkers,
leading to the development of a variety of proxy assays
[8–12]. Such low levels of circulating type I interferons pre-
sumably reflect their high biological potency, with most cells
expressing a type I interferon receptor.
Based on the initial work of others on SLE [13, 14], we
previously defined the characteristics of a test involving quan-
titative PCR (qPCR) assessment of six interferon-stimulated
genes (ISGs) using RNA extracted from PBMCs of patients
with AGS [15]. Here, we now report the use of this interferon
signature in a large cohort of patients and controls screened for
type I interferon signaling status. These data allow for a better
understanding of the practical application, interpretation, and
utility of such an assay, as well as an improved characteriza-
tion of the relationship of distinct diseases to type I interferon
and the core clinical features that should alert a physician to
the possibility of a type I interferon-related disorder.
Methods
Patient Cohort We tested patients, and in certain cases par-
ents and siblings to these patients, referred to us for assess-
ment of type I interferon status. Clinical and molecular data
were evaluated through direct contact and/or collected via
collaborating physicians. We included cases with molecularly
confirmed monogenic inflammatory diseases and a number of
patients with non-molecularly defined clinical phenotypes
which were either known to be, or we hypothesized might
be, associated with increased type I interferon signaling.
Control samples comprised an ethnically diverse group of
individuals who self-reported not to have any medical condi-
tion. We also included in our control group parents or siblings
to a person with an autosomal dominant interferonopathy
where the parent/sibling was negative for the familial muta-
tion. Neither patients nor controls demonstrated features of
infection at the time of sampling.
Interferon Score (IS) Blood was collected into PAXgene
tubes (PreAnalytix) and, after being kept at room temperature
for between 1 and 72 h, was frozen at −20 °C until extraction.
Total RNAwas extracted from whole blood using a PAXgene
(PreAnalytix) RNA isolation kit. RNA concentration was
assessed using a spectrophotometer (FLUOstar Omega,
Labtech). Quantitative reverse transcription polymerase chain
reaction (qPCR) analysis was performed using the TaqMan
Universal PCR Master Mix (Applied Biosystems) and
cDNA derived from 40 ng total RNA. Using TaqMan probes
for IFI27 (Hs01086370_m1), IFI44L (Hs00199115_m1),
IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2
(Hs01057264_m1), and SIGLEC1 (Hs00988063_m1), the
relative abundance of each target transcript was normalized
to the expression level of HPRT1 (Hs03929096_g1) and 18S
(Hs999999001_s1) and assessed with the Applied Biosystems
StepOne Software v2.1 and DataAssist Software v.3.01. For
each of the six probes, individual (patient and control) data
were expressed relative to a single calibrator (control C25)
(Table S1). The median fold change of the six ISGs, when
compared to the median of previously collected 29 healthy
controls, was used to create an IS for each individual.
Relative quantification (RQ) is equal to 2−ΔΔCt, i.e., the nor-
malized fold change relative to the control data. In this way,
we define an abnormal IS as being greater than +2 standard
deviations above the mean of this control group, i.e., 2.466.
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Statistics In the absence of a normal distribution, ISG levels
and ISs were log-transformed and analyzed with parametric
testing (t tests for two groups, one-way ANOVA for more than
two groups). Tests for multiple comparisons, Bonferroni’s
multiple comparison test or Dunnett’s multiple comparison
test as appropriate, were applied as detailed in the figure leg-
ends. GraphPad Prism version 6 for Mac OS X was used for
statistical analysis.
Ethics Approvals The study was approved by the Leeds
(East) Research Ethics Committee (reference number 10/
H1307/132) and by the Comité de Protection des Personnes
(ID-RCB/EUDRACT: 2014-A01017-40).
Results
Overall Cohort CharacteristicsOver a period of 6 years, we
tested a total of 2181 samples for an interferon signature.
These samples were from 1565 individuals, comprising 75
persons considered as controls (96 samples); 1264 patients
(1827 samples); and 209 parents (241 samples) and 17 sib-
lings (17 samples) of affected patients (Fig. 1).
We excluded the following from this total of 2181 samples:
187 samples from controls, parents, and siblings where data
on age, sex, or genotype were unavailable or where a proband
was also excluded (see below); 42 samples from 12 AGS
patients under treatment with reverse transcriptase inhibitors
(https://clinicaltrials.gov/ct2/show/NCT02363452?term=
Aicardi+Goutieres&rank=1); 51 samples from seven IFIH1-
and TMEM173-mutated patients under treatment with the
JAK1/2 inhibitor ruxolitinib [5]; 175, seven, and 13 results
from 161, seven, and 10 individuals with, respectively,
adult-onset SLE/mixed connective tissue disease, retinal vas-
culopathy and cerebral leukodystrophy (RVCL), and STAT1
gain-of-function mutations which were performed as part of
separate studies. We also excluded 714 samples from 597
patients where there was no genetic diagnosis and/or where
Fig. 1 Flow chart showing
inclusion/exclusion criteria for
study participation. The number
of measurements (samples) is
given, together with the number
of individuals/number of families
below/in brackets. Treatment*
refers to samples excluded
(n = 93) because patients were on
reverse transcriptase or JAK
inhibitors
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phenotypic data were limited/allowed for no definite clinical
diagnosis, there was no family history of similarly affected
relatives, and for whom we had tested less than three ISs.
Following the above exclusions, our cohort consisted of
992 samples from 630 individuals, specifically: 78 samples
from 65 controls (including 31 parents and seven siblings to
patients with a molecularly proven autosomal dominant type I
interferonopathy, most particularly due to heterozygous muta-
tions in TREX1, ADAR1, IFIH1, and TMEM173, where the
mutation was shown to have occurred de novo) (Table S1); 84
samples from 71 parents and five samples from five siblings
where the parent/sibling of a person with biallelic mutations in
a known type I interferonopathy-causing gene was shown to
be heterozygous for one familial mutation (Table S2); and 825
samples from 489 patients which we divided into three groups
for ease of analysis (Table 1). Group 1 comprises patients with
one or more interferon signature reading(s) and a confirmed
molecular diagnosis in any of the following 13 genes consid-
ered to have a proven link to type I interferon production/
signaling: TREX1 (Table S3), RNASEH2A (Table S4),
RNASEH2B (Table S5), RNASEH2C (Table S6), SAMHD1
(Table S7), ADAR1 (Table S8), IFIH1 (Table S9), ACP5
(Table S10), TMEM173 (Table S11), C1Q (Table S12), C2
(Table S12), ISG15 (Table S13), and SKIV2L (Table S14).
Of note, we only included patients with biallelic mutations
in these genes, except for those individuals with recognized
dominant mutations in TREX1 (at positions p.Asp18 and
p.Asp200), ADAR1 (at position p.Gly1007), IFIH1, and
TMEM173. In group 2, we included patients with a confirmed
molecular diagnosis of any other genotype, where at least one
patient from each of at least two different families tested pos-
itive for an interferon signature on at least one occasion. This
group thus comprised patients with mutations in DNASE1L3
(Table S15), PRKDC (Table S16), CECR1 (Table S17),
RNASET2 (Table S18), and TRNT1 (Table S19). Finally, in
group 3, we included patients with a clinical diagnosis of
juvenile SLE (JSLE) (Table S20); juvenile DM (JDM)
(Table S21); systemic juvenile idiopathic arthritis (sJIA)
(Table S24) and other, non-systemic, JIA (pJIA)
(Table S25); a molecularly undetermined phenotype which
was clinically labeled as autoinflammatory (defined here as
unexplained recurrent fevers and/or organ-specific features
Table 1 Summary data of median (and interquartile range, IQR) of interferon score in patients categorized by genotype/phenotype within each patient
group
Number of
samples/patients
Number (percentage)
with positive interferon scorea
Median (IQR)
Controls 78/65 7 (8.97%) 0.688 (0.427–1.196)
Group 1 patients combined 455/265 412 (90.55%) 10.73 (5.889–18.41)
TREX1 77/40 74 (96.10%) 10.89 (5.859–19.79)
RNASEH2A 11/5 11 (100%) 8.303 (4.215–19.59)
RNASEH2B 148/84 115 (77.70%) 6.101 (2.744–10.84)
RNASEH2B with positive score 115 7.731 (5.387–11.76)
RNASEH2C 16/13 16 (100%) 9.104 (6.819–13.78)
SAMHD1 45/31 45 (100%) 12.51 (9.215–16.53)
ADAR1 56/34 52 (92.86%) 16.16 (8.801–25.39)
IFIH1 59/26 59 (100%) 16.12 (11.15–22.03)
ACP5 17/12 14 (82.35%) 21.43 (3.264–32.26)
TMEM173 14/10 14 (100%) 16.05 (9.541–26.20)
C1Q 4/3 4 (100%) 16.86 (4.374–39.41)
C2 1/1 1 (100%) 11.90
ISG15 5/4 5 (100%) 21.24 (13.22–31.77)
SKIV2L 2/2 2 (100%) 24.67 (22.04–27.31)
Parents + siblings of group 1 patients 89/76 19 (21.35%) 0.862 (0.493–1.942)
Group 2 patients combined 30/17 23 (76.67%) 5.728 (2.604–9.805)
CECR1 11/5 9 (81.82%) 5.653 (3.349–7.053)
RNASET2 6/5 5 (83.33%) 4.288 (2.512–6.338)
PRKDC 6/2 5 (83.33%) 17.06 (4.582–22.29)
TRNT1 4/3 2 (50%) 4.048 (1.324–7.702)
DNASE1L3 3/2 2 (66.67%) 10.83 (0.374–11.00)
Group 3 patients combined 340/207 235 (69.12%)
JSLE 78/55 64 (82.05%) 10.60 (3.986–17.27)
JDM 101/59 76 (75.25%) 9.019 (2.507–21.73)
Molecularly undefined interferonopathy 72/24 67 (93.06%) 9.385 (6.675–13.98)
sJIA 21/19 6 (28.57%) 0.676 (0.496–6.421)
pJIA 10/9 0 (0%) 0.800 (0.387–1.074)
Autoinflammatory 58/41 22 (37.93%) 1.252 (0.590–4.064)
JSLE juvenile systemic lupus erythematosus, JDM juvenile DM, sJIA systemic juvenile idiopathic arthritis (JIA), pJIA non-systemic JIA
a Positive interferon score ≥2.466
126 J Clin Immunol (2017) 37:123–132
with elevated markers of systemic inflammation in the ab-
sence of autoimmunity and underlying infection)
(Table S23); and patients with a phenotype variably compris-
ing neurological, dermatological, rheumatological, and immu-
nological features reminiscent of the known type I
interferonopathy spectrum (Table S22), who screened nega-
tive for mutations in relevant type I interferonopathy-
associated genes and who demonstrated a positive IS on three
or more occasions or had a similarly affected relative with a
minimum of three positive ISs shared between affected family
members.
Results in ControlsOf 78 ISs from 65 controls, seven (9.0%)
were abnormal (median IS 0.688, IQR 0.427–1.196) (Table 1,
Table S1). In only two of these was the IS above five. The IS
was measured on more than one occasion in 12 control indi-
viduals, with three persons being sampled three times. On 26
of 27 occasions, the IS was normal (Figure S1), the one pos-
itive sample returning an IS of 23.4 which was normal on
repeat sampling. Controls ranged from 1 year to 93 years of
age and there was no correlation between age and IS (p =NS).
Thirty-five of 65 controls were female.
Results inGroup 1 In this group, wemeasured 455 interferon
signatures from 265 mutation-positive patients belonging to
222 families. All of these genotypes were associated with a
significant upregulation of type I interferon signaling (median
IS 10.73, IQR 5.90–18.41) (Table 1, Fig. 2a, Figure S2) com-
pared to controls. Thirty-three of 148 samples (22.30%) from
patients with mutations in RNASEH2B demonstrated a normal
IS, and a lower median IS (6.10, IQR 2.74–10.84) was ob-
served in this group compared to all other genotypes (median
IS 13.14, IQR 8.12–21.54), with the next lowest median ISs
associatedwithmutations in the two other proteins comprising
the RNase H2 complex. A comparison of the median RQ
value for each of the six individual ISGs across the genotypes
comprising group 1 revealed higher fold induction of IFI27
and SIGLEC1 in patients mutated in ACP5, TMEM173, C1Q,
and ISG15 compared to all other group 1 genotypes and to
patients in group 3 (Fig. 3).
Ten samples from patients mutated in TREX1 (two of 40
patients; three of 77 samples), ADAR1 (four of 34 individuals;
four of 56 samples), and ACP5 (two of 12 patients; three of 17
samples) also returned normal results (Fig. 2a, Table S26),
versus none of 95 patients (none of 157 samples) with the nine
other genotypes. We note that some, but not all, of these in-
terferon signature-negative patients demonstrated a milder
clinical phenotype in comparison with other cases mutated
in these same genes (data not shown). Of further note, one
of the two patients with ACP5-related disease with a normal
IS was on high-dose immunosuppressants and was reported to
have responded well clinically at the time of sampling.
Results in Group 2 In this group, we measured 30 interferon
signatures from 17 mutation-positive patients belonging to 14
families (Fig. 2b, Figure S3). For each of the five genotypes,
CECR1 (11 samples, five patients), RNASET2 (six samples,
five patients), PRKDC (six samples, two patients), TRNT1
(four samples, three patients), andDNASE1L3 (three samples,
two patients), we recorded positive ISs in at least one patient
from each of at least two different families (Fig. 2b).
Results in Group 3 Group 3 includes patients with molecu-
larly undefined phenotypes, where we measured 340 interfer-
on signatures from 207 patients belonging to 187 families
(Fig. 2c, Figure S4). Our data mirror the results from multiple
studies demonstrating an upregulation of interferon signaling
in a significant proportion of individuals with JSLE and JDM,
where 82% (64 of 78) and 75% (76 of 101) of samples were
abnormal in these two phenotypic groupings, respectively
Fig. 2 Interferon score plotted for each sample according to genotype/
phenotype. a 455 group 1 patient samples. b 30 group 2 patient samples. c
340 group 3 patient samples. Black horizontal lines represent the median
for each patient group. Interferon scores calculated from the median fold
change in RQ (relative quantification) values of a panel of six interferon-
stimulated genes (ISGs). Blue dots represent an interferon score of less
than 2.466. Red dots represent an interferon score of greater than 2.466.
Magenta dots represent patients treated with IL1 blockade. Analyzed by
one-way ANOVAwith Dunnett’s multiple comparison test
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(JSLE: median IS 10.60, IQR 3.99–17.27; JDM: median IS
9.02, IQR 2.51–21.73) (Table 1). We note that a number of
these patients were under treatment, and some had clinically
quiescent disease at the time of sampling. In contrast, a lower
proportion (14 of 41) of patients with a clinical diagnosis of a
non-molecularly determined autoinflammatory phenotype
returned a positive IS (median 1.25, IQR 0.59–4.06).
Considering another complex disease, sJIA, we identified five
of 19 patients with a positive IS, 11 of whom were being
treated with interleukin 1 (IL1) blockade. Finally, we also
included in this group 72 samples from 24 patients belonging
to 17 families who did not carry a mutation in known clini-
cally relevant type I interferonopathy-associated genes and
where we recorded an upregulation of type I interferon signal-
ing measured on at least three occasions—thus, likely indica-
tive of a true association with enhanced type I interferon sig-
naling (median IS 9.38, IQR 6.67–13.98).
Results in Parents and Siblings of Patients in Group 1 The
large majority of samples from proven heterozygous carrier
parents (66 of 84 samples) and siblings (four of five samples)
to patients with biallelic mutations in AGS1-7 and ACP5 did
not demonstrate an interferon signature (median IS 0.862,
IQR 0.493–1.942) (Figure S5). Ten of the 18 abnormal paren-
tal signatures were recorded in individuals heterozygous for a
mutation in ADAR1.
Discussion
We present an overview of our experience of screening a
large cohort of patients and controls for an induction of
type I interferon signaling in whole blood by quantifying
the expression of six ISGs—IFI27, IFI44L, IFIT1, ISG15,
RSAD2, and SIGLEC1. There is no consensus as to the
precise set of genes to measure when testing for an inter-
feron signature. Nor is there a universally accepted
method for calculating an IS based on a composite of
multi-gene transcript upregulation. Prior to this study,
we measured the expression of 15 ISGs in patients with
mutations in ADAR1 [16]. Based on those results, and a
series of unpublished genome-wide expression experi-
ments, we then focused on six ISGs that were highly
expressed in individuals from a cohort of molecularly de-
fined AGS patients [15]. The median fold change of the
six ISGs compared to the median of 29 healthy controls
was used to create an IS for each patient, with a value
greater than two standard deviations above the mean score
of the controls (>2.466) being designated as positive. In
this previously published work, we also showed that our
IS positively correlated with an assay of anti-viral cyto-
pathic protection.
The extended control data set presented here confirms
that the large majority of healthy persons do not demon-
strate an upregulation of type I interferon signaling, irre-
spective of age or sex. In contrast, work published by
many groups has shown that enhanced type I interferon
signaling is a reliable biomarker of a number of clinical
phenotypes [13, 14, 17]. Given that our data recapitulate
the results of these genome-wide expression studies, we
consider that the simple screening assay presented here
has validity as a tool that can differentiate patients from
controls according to type I interferon status, frequently in
the absence of any other indices of inflammation.
Although ISG transcripts can be induced by infection,
effectively resulting in a Bfalse positive^ result in the sit-
uations under consideration here, our data show that the
IS is reproducible and consistent over time in the large
majority of cases. Thus, taking all individuals in whom
we recorded more than one IS, repeat sampling in 91 of
108 patients with a monogenic interferonopathy was con-
sistent for a positive/negative IS (with nine of the 17
patients demonstrating discordant results being mutated
in RNASEH2B). Furthermore, in 19 patients mutated in
Fig. 3 Median fold expression of six interferon-stimulated genes accord-
ing to genotype. Median relative quantification (RQ) value for each of six
interferon-stimulated genes (ISGs) measured in a 74 TREX1, 11
RNASEH2A, 115 RNASEH2B, 16 RNASEH2C, 45 SAMHD1, 52
ADAR1, and 59 IFIH1 samples with a positive (>2.466) interferon score;
b 14 ACP5, 14 TMEM173, four C1QA, and five ISG15 samples with a
positive (>2.466) interferon score; c 101 JDM, 21 sJIA, 58
autoinflammatory, 72 molecularly undefined interferonopathy, 78 JSLE,
and ten pJIA. RQ is equal to 2−ΔΔCt, i.e., the normalized fold change
relative to a control
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any of AGS1-7 where we recorded four or more serial
measurements, the scores were consistently positive in
all cases—over periods spanning between 4 months and
more than 3 years (Fig. 4). Indeed, we have shown pre-
viously that such repeat testing can enable the identifica-
tion of new disease genes [18] and the definition of novel
genotype-phenotype associations [19].
Our group 1 comprises 13 genotypes in which a link to
enhanced interferon signaling seems established—TREX1
[20], RNASEH2A, RNASEH2B, RNASEH2C [21], SAMHD1
[22], ADAR1 [16], IFIH1 [18], ACP5 [23, 24], TMEM173
[25], C1Q [26], C2, ISG15 [27], and SKIV2L [28]. Although
we group these genotypes for ease of analysis, it is interesting
that a comparison of the median RQ value for each of the six
individual ISGs revealed markedly higher fold induction of
IFI27 and SIGLEC1 in patients mutated in ACP5, TMEM173,
C1Q, and ISG15 compared to all other group 1 genotypes and
to patients in group 3 (Fig. 3). This observation suggests
genotype-specific patterns of ISG induction which are worthy
of further interrogation, using genome-wide expression ar-
rays, in a larger number of patients. We point out here that
our cohort does not represent a survey of all putative mono-
genic type I interferonopathies, since we have yet to assess
any patients with mutations in PSMB8, PSMB4, PSMA3 [29],
DDX58 [30], POLA1 [31], orUSP18 [32] using our screening
assay [33].
In group 1, we measured 455 interferon signatures
from 265 mutation-positive patients, of which 412
samples (91%) were abnormal. Of the 43 data points fall-
ing within the normal range, 33 were from patients mu-
tated in RNASEH2B (Fig. 2, Table S26). As such, a nor-
mal result does not rule out a diagnosis of these discrete
monogenic interferonopathies. However, a positive IS is
clearly a reliable disease biomarker and can serve as a
useful diagnostic screening tool.
The rationale for our group 2 designation was to try to
identify further monogenic diseases demonstrating a consis-
tent association with upregulated type I interferon signaling,
where there is currently no biological evidence for such a link.
For inclusion in this group, we required that at least one pa-
tient from each of at least two different families with the same
monogenic disease demonstrated an upregulation of type I
interferon signaling on at least one occasion. This allowed
us to suggest that there might be a positive correlation of
interferon induction with mutations in CECR1 [34, 35],
RNASET2 [36, 37], PRKDC [38], TRNT1 [39], and
DNASE1L3 [40, 41]. However, the small number of patients
from whom we received repeat samples means that these pu-
tative associations need to be evaluated in larger cohorts of
patients.
Mutations in the genes included in our group 1 can be
associated with a remarkably broad spectrum of discrete
or combined neurological, rheumatological, and dermato-
logical presentations. Informed by these data, we identi-
fied a group of 24 patients from 17 families demonstrating
a consistent upregulation of type I interferon signaling
Fig. 4 Interferon scores in patients where four or more serial samples
were recorded. Data shown are interferon scores plotted against time
(years) since first sampling. Interferon scores are calculated from the
median fold change in relative quantification (RQ) values for a panel of
six interferon-stimulated genes (ISGs). The blue dashed line represents
the boundary of a positive/negative score (2.466). The number of serial
samples for each patient is shown in brackets in the legend
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(median IS 9.38, IQR 6.67–13.98), all of whom tested
nega t ive fo r known c l in i ca l ly re l evan t type I
interferonopathy-associated genes. Considering the occur-
rence of affected siblings in four of these families, there is
a high likelihood that certain of these patients have a
currently undefined genetic basis to their disease.
Important clinical indicators that should prompt consider-
ation of this type I interferonopathy grouping include vas-
culitic skin lesions, intracranial calcification, spasticity,
dystonia, glaucoma, recurrent fevers, interstitial lung dis-
ease, and lupus-like disease.
We did not collect enough samples from any monogenic
entities to make a definitive statement on a null relation-
ship to type I upregulation. However, we did test a group of
41 patients clinically defined as having autoinflammatory
disease, the majority of whom (27 of 41) showed no evi-
dence of enhanced type I interferon signaling at any time
(median IS 1.25, IQR 0.59–4.06). These data lend support
to the specificity of type I interferon-induced gene tran-
script measurement as a screening tool and lead us to sug-
gest that autoinflammation can be both interferon (e.g., due
to mutations in IFIH1 and TMEM173) and non-interferon
re la ted . Indeed, the only chi ld inc luded in our
autoinflammatory group with a convincing upregulation
of interferon signaling on multiple occasions (Table S23,
AGS818) demonstrated recurrent chilblain-like lesions
highly evocative of other type I interferonopathies.
While most patients with AGS are not currently treated
by immunosuppression, a limitation of our study is that a
majority of patients in groups 2 and 3 were receiving such
therapy (details of which, where available, are given in
S20, S21, S23, S24, and S25) when tested for an interfer-
on signature. The possibility that such immunosuppres-
sion might attenuate a disease-associated upregulation of
type I interferon signaling has been alluded to above.
However, it is of note that many patients with JSLE and
JDM demonstrated persistent upregulation of interferon
signaling despite treatment. Interestingly, although sJIA
is not normally associated with a type I interferon signa-
ture [42], we observed an upregulation of ISG expression
in a small number of cases treated with IL1 blockers. This
finding is concordant with a previous description of the
induction of an interferon signature in JIA patients treated
with anakinra and likely reflects currently undefined feed-
back loops triggered by these anti-cytokine agents [43].
As evidenced by the risk of developing interferon-driven
pathology in the context of TNF-α blockade [44], such
changes can be of clinical importance.
Summarizing, taken in clinical context, testing for an
interferon signature represents a reliable screening tool for
the identification of a variety of distinct genotypes and
phenotypes. Such testing will likely become of high im-
portance as therapies based on blocking interferon
signaling become available [5, 45]. The interferon assay
that we describe is practical, with the PAXgene system
being stable for at least 72 h at room temperature, thus
allowing for the easy transfer of samples to a reporting
laboratory. At the same time, the IS represents a proxy
assay, i.e., it does not directly measure the relevant
disease-inducing molecule(s). Thus, we await the intro-
duction of high-sensitivity assays of interferon protein
which will be usefully combined with measures of ISG
production as described here, thereby capturing the rela-
tionship between the inducing signal and the response to
that signal.
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